FDA Seeks Public Input To Support Ibogaine Research

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA has opened a 45-day public comment period on approaches for designing early-phase clinical trials of ibogaine drug products. The agency is seeking information on study populations, dosing, safety protections and oversight; the request does not approve ibogaine as a treatment or establish that it is safe or effective.

The U.S. Food and Drug Administration is asking the public for data and comments on how early-phase clinical trials of ibogaine drug products should be designed, including their dosing and safety measures. The request for information, announced October 5, is intended to inform research planning; it is not an approval of ibogaine for medical use.

The FDA is seeking feedback on four broad areas: general study design and patient populations; dose selection and escalation; safety protections; and ethical and oversight practices. The agency says the questions include where trials should take place, who should be eligible, what monitoring is needed, and what stopping rules and independent safety oversight should apply.

On dosing, the FDA is seeking input on a possible approach using small, sequential dose-ascending groups. It says a proposed starting dose should be justified by available data and not exceed 10 milligrams per kilogram. This is a topic for public comment, not a final dosing rule or recommendation for treatment outside a clinical trial.

Safety questions include how trials should monitor for cardiac and neurologic adverse events and what other safeguards are warranted. The request also covers informed consent and independent safety oversight. The FDA says submissions may help it better understand potential uses, benefits and risks and inform drug-development approaches. The comment period lasts 45 days after publication in the Federal Register and closes Friday, November 20, 2026. Comments can be filed electronically at Regulations.gov under docket FDA-2026-N-10429, or sent in writing to the agency’s Dockets Management Staff in Rockville, Maryland.

Safety Questions Shape Trial Planning

The request addresses practical decisions that can affect whether early ibogaine studies are designed to gather useful evidence while limiting risks to participants. Input on dose escalation, cardiac and neurologic monitoring, eligibility and stopping rules could help the FDA assess what protections and data sponsors should consider when planning trials.

The agency says it recognizes the unmet needs of people seeking ibogaine treatment, while also pointing to serious safety concerns and unanswered scientific questions. The distinction matters: this process supports consideration of research design, not a finding that ibogaine works for opioid use disorder, post-traumatic stress disorder or another condition. Any treatment claim would require evidence from research and review through the relevant regulatory process.

For patients and families, the announcement may signal increased federal attention to studying ibogaine, but it does not authorize a new therapy or establish that care outside a clinical trial is safe. For researchers and sponsors, the comment period offers a route to submit evidence and raise design questions before the agency settles on approaches for early-phase studies.

Federal Research Efforts Underway

The FDA describes the request as part of federal efforts following an April 2026 executive order on accelerating medical treatments for serious mental illness, which directed agencies to advance research into psychedelic medicine. The agency says its work is intended to proceed through evidence-based processes.

In July 2026, the FDA finalized guidance for industry, “Psychedelic Drugs: Considerations for Clinical Investigations,” offering general considerations for sponsors developing psychedelic drugs. Separately, the FDA has allowed an early-phase study of noribogaine hydrochloride—a derivative of ibogaine—to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder. That study is distinct from the new request for public input.

Other federal work is also underway, according to the FDA. The Department of Health and Human Services, through ARPA-H, is funding a program to collect safety and efficacy data in early-phase psychedelic trials, while the National Institute on Drug Abuse is funding ibogaine research for the potential treatment of opioid use disorder. HHS has identified adults with opioid use disorder and adults with PTSD as initial populations for federally supported research, based on available data and the seriousness of those conditions.

“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.”

— Michael Davis, director of the FDA’s Center for Drug Evaluation and Research

Evidence and Risks Still Need Study

The request does not resolve whether ibogaine is safe or effective for any condition. The FDA says it is seeking information to better understand possible uses, benefits and risks; the announcement does not provide findings that establish clinical benefit or quantify the risks.

It is also not yet clear what changes, if any, the agency will make to its approaches after reviewing public submissions. The proposed dose-escalation model and 10 mg/kg ceiling are among the issues on which the FDA seeks input, not finalized requirements. The scope and timing of future ibogaine trials beyond the activity described by the agency are not specified in the announcement.

Public Comments Close November 20

Interested researchers, patients, clinicians and other stakeholders can submit comments, data or information during the 45-day comment period. Electronic submissions go through Regulations.gov by searching for Docket No. FDA-2026-N-10429. Paper submissions may be sent to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.

The FDA says late comments will not be considered; the docket closes November 20, 2026. The agency’s announcement does not give a date for a later response or decision. Subsequent trial-development steps will depend on the evidence and feedback received and on the relevant regulatory processes.

Key Questions

Has the FDA approved ibogaine as a treatment?

No. The FDA announced a request for information on early-phase trial design. It is not an approval of ibogaine for medical use.

What is the FDA asking the public to comment on?

The agency seeks input on study design and patient populations, dose selection and escalation, safety monitoring, and ethical and independent oversight, among other protocol details.

What dose is the FDA proposing?

The FDA is asking about an approach with small, sequential dose-ascending groups and a starting dose justified by available data that does not exceed 10 mg/kg. This is a subject for comment, not a final dose instruction.

When and how can comments be submitted?

Comments are due by Friday, November 20, 2026. Submit electronically through Regulations.gov using docket FDA-2026-N-10429, or send a paper submission to the FDA’s Dockets Management Staff in Rockville, Maryland.

Which patient groups are named for federally supported research?

The FDA says HHS is prioritizing adults with opioid use disorder and adults with post-traumatic stress disorder for initial federally supported research. This does not establish that ibogaine is an effective treatment for either condition.

Source: primary